| |
Newsroom /
Health and Fitness
/
Healthcare
/
PRECISION THERAPEUTICS TO PRESENT AT JEFFRIES 2010 GLOBAL HEALTHCARE SERVICES CONFERENCE
PRECISION THERAPEUTICS TO PRESENT AT JEFFRIES 2010 GLOBAL HEALTHCARE SERVICES CONFERENCE
Precision Therapeutics, Inc. today announced that CEO Sean McDonald plans to provide a company presentation to the Jeffries 2010 Global Healthcare Services Conference at the Mandarin Oriental Hotel in New York City on Monday, January 25, 2010.
Pittsburgh,
PA,
India
(prbd.net)
26/01/2010
"Precision Therapeutics, Inc. today announced that CEO Sean McDonald plans to provide a company presentation to the Jeffries 2010 Global Healthcare Services Conference at the Mandarin Oriental Hotel in New York City on Monday, January 25, 2010."
Precision Therapeutics, Inc. today announced that CEO Sean McDonald plans to provide a company presentation to the Jeffries 2010 Global Healthcare Services Conference at the Mandarin Oriental Hotel in New York City on Monday, January 25, 2010. The presentation may include a discussion of the company’s marketed products, strategy for growth, pipeline, financial results and expectations, and other matters relating to the personalized medicine industry.
Precision Therapeutics, headquartered in Pittsburgh, Pennsylvania, is a life science company and leader in the development of innovative technology that delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions in cancer therapy.
Precision’s ChemoFx®, a proprietary drug response marker, measures an individual patient’s tumor response to various chemotherapeutic and biological agents prior to treating the patient. ChemoFx® can complement the physician’s experience and provide valuable patient-specific information, particularly when there is non-uniform response to standard cancer treatment or no clear choice for the next regimen.
For more information:
http://www.precisiontherapeutics.com
http://www.chemofx.com
###
About
Precision Therapeutics is a CLIA-certified diagnostics services company dedicated to providing physicians and patients with actionable clinical information to (http://www.chemofx.com/cancer-treatment/why-chemotherapy.html) personalize cancer treatments. Precision’s ChemoFx®, a proprietary live tumor cell-based platform, measures an individual patient’s tumor sensitivity and resistance to a range of therapeutic alternatives under consideration by a physician. This may help guide physicians when e
|